– USA, VA – CEL-SCI Corporation (NYSE:CVM) announced today that healthcare information technology executive Robert Watson has joined the Company’s Board of Directors.
Mr. Watson has over 35 years of experience in the healthcare IT industry as a CEO, board member and advisor to multiple companies. Having participated in over 75 acquisitions, he has raised nearly $750,000,000 in capital, completed three public offerings and successfully sold four companies.
Currently, Mr. Watson is President of the Preparedness Technology Division at Intermedix. Prior, he was the President and Chief Growth Officer of NantHealth, and CEO of Streamline Health, both NASDAQ listed companies. He has held executive positions at numerous other healthcare IT companies.
Mr. Watson holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BA from Syracuse University.
“I am excited to join CEL-SCI’s board at this time, as the Company approaches evaluating the endpoint of its Phase 3 results, which may lead to a new and much needed immunotherapy to treat head and neck cancer. The impact CEL-SCI and its investigational immunotherapy Multikine* can have in the cancer treatment market and in improving the quality of life of patients living with the disease may be enormous. I am pleased to contribute my expertise in supporting CEL-SCI,” stated Robert Watson.
“We are so pleased that Robert has joined our board. He brings a depth of knowledge and experience that we believe will add significant value to our board and our Company. His experience encompasses executive leadership at large public companies and the start-up, growth and sale of healthcare companies, as well as investment banking. We welcome him to our board,” CEL-SCI CEO Geert Kersten added.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient’s immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine, BEFORE they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried and/or failed. Head and neck cancer represents about 6% of all cancers. Multikine has received Orphan Drug designation from the FDA for the treatment of head and neck cancer patients with advanced squamous cell carcinoma.
The Company’s LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. CEL-SCI has patents on Multikine from the US, Europe, China, and Japan.
The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information : http://www.cel-sci.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
